UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2 )*
Cellegy Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
15115L-10-3
-------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
<TABLE>
SCHEDULE 13G
<CAPTION>
<S> <C>
- ----------------------------------------------- ---------------------------------------------
CUSIP No. 15115L-10-3 Page 2 of 9 Pages
- ----------------------------------------------- ---------------------------------------------
- --------- --------------------------------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS
1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Sundance Venture Partners, L.P.
- --------- --------------------------------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) |_|
(b) |X|
- --------- --------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- --------- --------------------------------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
- --------------------------- ------- ------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER -0-
OF
------- ------------------------------------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY 399,816
OWNED
------- ------------------------------------------------------------------------------
BY 7 SOLE DISPOSITIVE POWER
EACH -0-
REPORTING
------- ------------------------------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 399,816
- --------------------------- ------- ------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
399,816
- --------- --------------------------------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |_|
- --------- --------------------------------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.95%
- --------- --------------------------------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
PN
- --------- --------------------------------------------------------------------------------------------------------
</TABLE>
Page 2 of 9
<PAGE>
<TABLE>
SCHEDULE 13G
<CAPTION>
<S> <C>
- ----------------------------------------------- ---------------------------------------------
CUSIP No. 15115L-10-3 Page 3 of 9 Pages
- ----------------------------------------------- ---------------------------------------------
- --------- --------------------------------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS
1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Anderson & Wells Company
- --------- --------------------------------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) |_|
(b) |X|
- --------- --------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- --------- --------------------------------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
- --------------------------- ------- ------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER -0-
OF
------- ------------------------------------------------------------------------------
SHARES 6 SHARED VOTING POWER 399,816
BENEFICIALLY Anderson & Wells Company is the sole General Partner of
Sundance Venture Partners, L.P.
------- ------------------------------------------------------------------------------
BY 7 SOLE DISPOSITIVE POWER
EACH -0-
REPORTING
------- ------------------------------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER 399,816
WITH Anderson & Wells Company is the sole General Partner of Sundance Venture
Partners, L.P.
- --------------------------- ------- ------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
399,816
- --------- --------------------------------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |_|
- --------- --------------------------------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.95%
- --------- --------------------------------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
CO
- --------- --------------------------------------------------------------------------------------------------------
</TABLE>
Page 3 of 9
<PAGE>
Item 1.
(a) Name of Issuer:
Cellegy Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
1065 East Hillsdale Blvd., Suite 418, Foster City, CA 94404
Item 2.
(a) Name of Person Filing:
Sundance Venture Partners, L.P.
(b) Address of Principal Business Office:
10600 N. DeAnza Boulevard, Suite 215, Cupertino, CA 95014
(c) Citizenship:
U.S.A.
(d) Title of Class of Securities:
Common Stock
(e) CUSIP Number:
15115L-10-3
Item 3.
Not applicable.
Item 4. Ownership
(a) Amount Beneficially Owned: 399,816
(b) Percent of Class: 3.95%
(c) Number of shares as to which such person has:
(i) sole power to vote or direct the vote: -0-
(ii) shared power to vote or direct the vote: 399,816
(iii) sole power to dispose or to direct the
disposition of: -0-
(iv) shared power to dispose or to direct the
disposition of: 399,816
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following [x].
Item 6. Ownership of More Than Five Percent on Behalf of Another
Person
Not applicable
Page 4 of 9
<PAGE>
Item 7. Identification and Classification of Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company
Not applicable.
Item 8. Identification and Classification Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below, I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired in
the ordinary course of business and were not acquired for the
purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and
were not acquired in connection with or as a participant in
any transaction having such purposes or effect.
Page 5 of 9
<PAGE>
Item 1.
(a) Name of Issuer:
Cellegy Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
1065 East Hillsdale Blvd., Suite 418, Foster City, CA 94404
Item 2.
(a) Name of Person Filing:
Anderson & Wells Company (General Partner of Sundance
Venture Partners, L.P.)
(b) Address of Principal Business Office:
400 East Van Buren, Suite 750, Phoenix, AZ 85004
(c) Citizenship:
U.S.A.
(d) Title of Class of Securities:
Common Stock
(e) CUSIP Number:
15115L-10-3
Item 3.
Not applicable.
Item 4. Ownership
(a) Amount Beneficially Owned: 399,816
(b) Percent of Class: 3.95%
(c) Number of shares as to which such person has:
(i) sole power to vote or direct the vote: -0-
(ii) shared power to vote or direct the vote: 399,816
(iii) sole power to dispose or to direct the
disposition of: -0-
(iv) shared power to dispose or to direct the
disposition of: 399,816
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the
following. [x]
Item 6. Ownership of More Than Five Percent on Behalf of Another
Person
Not applicable
Page 6 of 9
<PAGE>
Item 7. Identification and Classification of Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company
Not applicable.
Item 8. Identification and Classification Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below, I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired in
the ordinary course of business and were not acquired for the
purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and
were not acquired in connection with or as a participant in
any transaction having such purposes or effect.
Page 7 of 9
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: February 12, 1998
SUNDANCE VENTURE PARTNERS, L.P.
By: /s/ Larry J. Wells
- -----------------------------------
Larry J. Wells
ANDERSON & WELLS COMPANY
By: /s/ Larry J. Wells
- -----------------------------------
Larry J. Wells
See attached Exhibit A
Page 8 of 9
<PAGE>
EXHIBIT A
Agreement of Joint Filing
The undersigned hereby agree that they are filing jointly, pursuant to
Rule 13d-1 of the Securities Exchange Act of 1934 the statement dated February
__, 1998, containing the information required by Schedule 13G, for the 399,816
shares of the Common Stock of Cellegy Pharmaceuticals, Inc. held by Sundance
Venture Partners, L.P. and Anderson & Wells Company, the sole General Partner of
Sundance Venture Partners, L.P.
Date: February ___, 1998
SUNDANCE VENTURE PARTNERS, L.P.
By: /s/ Larry J. Wells
- -----------------------------------
Larry J. Wells
ANDERSON & WELLS COMPANY
By: /s/ Larry J. Wells
- -----------------------------------
Larry J. Wells
Page 9 of 9
